RT Journal Article
SR Electronic
T1 Variability of total serum IgE in moderate-to-severe asthmatic patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4171
DO 10.1183/13993003.congress-2016.PA4171
VO 48
IS suppl 60
A1 Louis, Renaud
A1 Pilette, Charles
A1 Michel, Olivier
A1 Michils, Alain
A1 Brusselle, Guy
A1 Dupont, Lieven
A1 Poskin, Antoine
A1 Van Schoor, Jan
A1 Vancayzeele, Stefaan
A1 Gurdain, Sandra
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA4171.abstract
AB Long-term variability of serum total IgE (sIgEtot) has been reported in asthmatics. This study evaluates the dynamics and the factors predictive of this variability.sIgEtot levels were prospectively measured over 1 year in 41 moderate-to-severe asthmatics treated with high-dose of inhaled corticosteroids and long-acting β2 agonists (and untreated with omalizumab). Patients were divided into 3 groups according to their baseline sIgEtot level: low (≤75 IU/mL; n=10), intermediate (76-700 IU/mL; n=20) or high (>700 IU/mL; n=11). The sIgEtot variability and factors predictive of IgEtot variability were studied.The mean sIgEtot (whole group) fluctuated over 1 year and showed an overall non-significant decrease from baseline (p=0.21). Four to 29% of the sIgEtot variability depended on within-patient variability. No factor predictive of the within-patient variability was identified in the intermediate sIgEtot group. In the low sIgEtot group, however, the level of sIgEtot increased over 1 year in patients exposed to allergens (p<0.001) or who used oral corticosteroids (OCS) (p=0.011), and the odds of having an exacerbation since the previous visit increased by 30% if sIgEtot increased by 100 IU/mL (p<0.0001). Unexpectedly, in the high sIgEtot group, the odds of having an exacerbation since the previous visit decreased by 5% if sIgEtot increased by 100 IU/mL (p=0.005). These trends should be confirmed in a bigger cohort.In this small cohort of moderate-to-severe asthmatics, a limited within-patient variability of sIgEtot levels was observed over 1 year. This variability depended on allergen exposure, OCS use (probably related to exacerbation management) and exacerbations in patients with low and high baseline sIgEtot.